The group’s principle activity is to integrate modern molecular, genomic, biophysical, and diagnostic techniques with animal models of Central Nervous System disease in order to discover new compounds for the treatment of a variety of neurological disorders. The group also provides solutions for Central Nervous System disorders and diseases affecting attention, learning, and memory including Alzheimer's disease. The group operates from United States.
